drugset / Trial / NCT05520177
A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
RandomizedParallel-groupTriple-blindTreatment
Summary
To compare the efficacy and safety of recombinant humanized anti-VEGF monoclonal antibody (601) with Ranibizumab in patients with macular edema secondary to BRVO
Timeline
- Start
- 2022-12-27
- Primary completion
- 2024-09-23
- Completion
- 2024-09-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 601 | Monoclonal antibody | 1.25 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |